Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Diabetes and Endocrinology, P.A.

Neither a doctor nor a teaching hospital

Research payments

$143,363

87 payments

Through program year 2025, Texas Diabetes and Endocrinology, P.A. is reported as receiving $143,363 in research payments, across 87 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$18,125	54
2024	Research	$40,039	10
2023	Research	$8,202	5
2021	Research	$985	2
2020	Research	$51,942	2
2019	Research	$24,070	14

Breakdown

Who paid Research payments · program years 2019–2025

Senseonics, Incorporated $66,366 69 payments
Becton, Dickinson and Company $52,927 4 payments
Sanofi US Services Inc. $24,070 14 payments

Studies the money was for Research payments · program years 2019–2025

Bright $51,942 2 payments
Senseonics CTP0039 $35,492 9 payments
Senseonics CTP0034 PAS $14,702 7 payments
Senseonics CTP-0034 $12,791 42 payments
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder $9,939 4 payments
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period $7,060 5 payments
A 26-Week Open-label Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agoni $3,690 2 payments
Senseonics CTP-0039 $3,381 11 payments
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder $3,381 3 payments
Zodiac $985 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.